[Table_Industry] 金融 [Table_Invest] 评级： 增持 ——众安在线 2024 年年报业绩点评 本报告导读： 公司 24 年净利润同比 105.4%（剔除同期众安国际并表影响），预计主要得益于承保 盈利贡献，投资收益提振，科技及银行盈利改善。维持"增持"。 投资要点： 催化剂：资本市场回暖。 利润显著改善，AI 打造增长曲线 众安在线(6060) | [table_Authors] 刘欣琦(分析师) | 李嘉木(分析师) | | | | --- | --- | --- | --- | | | | [当前价格 Table_CurPrice] (港元)： | 13.82 | | 021-38676647 | 021-38038619 | | | | liuxinqi@gtjas.com | lijiamu026075@gtjas.com | [Table_Market] | | | 登记编号 S0880515050001 | S0880524030003 | 交易数据 | | 风险提示：长端利率下行；赔付率提升；虚拟银行盈利不及预期。 -26% -8% 10% 27% 45% 63% ...

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of HKD 44.00, indicating a potential upside of 84.1% from the current price of HKD 23.90 [2][3][10]. Core Insights - The company is expected to achieve profitability again in 2024, driven by strong overseas sales of Furmonertinib and effective cost control measures. The focus for 2025 will be on the NDA submission for SAVANNAH in the U.S. and the progress of new product approvals in mainland China [3][7]. - Despite a decline in one-time collaboration income, the company has managed to maintain a positive outlook due to robust sales performance and cost management [3][7]. - The company’s revenue for 2025 is projected at USD 708 million, with a slight decrease from previous estimates, while net profit is expected to rise significantly to USD 452 million, reflecting a 15% increase from prior forecasts [6][12]. Financial Projections - Revenue and profit forecasts for 2025-2027 show a slight downward adjustment of 1-4% for revenue, but an increase in net profit projections due to ongoing cost control efforts [7][12]. - The company anticipates oncology and immunology revenue to reach USD 350-450 million in 2025, with a projected growth of over 30% in product market sales [7]. - The DCF model estimates the company's equity value at approximately USD 4.916 billion, translating to a per-share value of HKD 44.00 [8][12]. Market Performance - The stock has shown a year-to-date increase of 5.99%, with a 52-week high of HKD 34.70 and a low of HKD 20.25 [5][11]. - The report highlights the significant growth in oncology product revenue, which increased by 65% year-on-year, primarily due to the strong market performance of Furmonertinib [7][12].

Investment Rating - The investment rating for ZTO Express (2057.HK) is "Buy" [1] Core Views - The report highlights ZTO Express's strong market position, with a leading market share of approximately 19.4% in the express delivery sector, despite a slight year-on-year decline of 1.5% [3][5] - The company achieved an adjusted net profit of 10.2 billion yuan in 2024, representing a year-on-year increase of 12.7% [2][4] - ZTO Express is expected to maintain robust growth, with projected business volume for 2025 estimated between 40.8 billion and 42.2 billion pieces, reflecting a year-on-year growth of 20% to 24% [5][7] Financial Performance - In 2024, ZTO Express reported total revenue of 44.281 billion yuan, a year-on-year increase of 15.3% [2][9] - The adjusted net profit for 2024 was 10.15 billion yuan, with a quarterly performance in Q4 showing a revenue of 12.92 billion yuan, up 21.7% year-on-year [2][4] - The company’s single-piece express revenue increased by 2.5% year-on-year to 1.20 yuan, with Q4 showing a more significant increase of 11.0% to 1.24 yuan [3][4] Operational Metrics - ZTO Express handled 34 billion pieces in 2024, marking a year-on-year growth of 12.6% [3][5] - The company’s single-piece express cost decreased by 6.0% year-on-year to approximately 0.68 yuan, benefiting from economies of scale and improved route planning [4] - The adjusted net profit per single piece remained stable at 0.30 yuan for the year, with Q4 showing an increase of 11.2% to 0.28 yuan [4] Market Outlook - The express delivery industry is expected to continue growing, with an estimated industry volume growth of 10-15% in 2025 [7] - ZTO Express is well-positioned to enhance its market share and profitability, supported by its scale and management advantages [8] - The report anticipates that ZTO Express will achieve adjusted net profits of 10.44 billion yuan, 11.78 billion yuan, and 13.51 billion yuan for 2025, 2026, and 2027, respectively, indicating a steady growth trajectory [8][9]

Investment Rating - The report maintains a "Buy" rating for the company, indicating a potential upside of 21% based on a target market capitalization of 34.7 billion HKD for 2025 [6][12]. Core Insights - The company achieved a revenue of 8.12 billion CNY in 2024, representing a year-on-year growth of 16%. However, it reported a net loss of 210 million CNY primarily due to goodwill impairment of 1.1 billion CNY from New Classics Media [1][6]. - Adjusted net profit, excluding the impact of goodwill impairment, was 1.14 billion CNY, showing a slight increase of 1% year-on-year [1][6]. - The online reading business stabilized with a revenue of 4.03 billion CNY in 2024, marking a 2% increase, while the paid reading segment grew by 3% [6]. Financial Data and Profit Forecast - Revenue projections for the company are as follows: - 2023: 7.012 billion CNY - 2024: 8.121 billion CNY - 2025E: 8.164 billion CNY - 2026E: 8.591 billion CNY - 2027E: 9.056 billion CNY - Adjusted net profit forecasts are: - 2023: 1.13 billion CNY - 2024: 1.14 billion CNY - 2025E: 1.28 billion CNY - 2026E: 1.42 billion CNY - 2027E: 1.56 billion CNY [3][7]. Business Developments - New Classics Media's goodwill risk has been released, with a reported net profit of 340 million CNY in 2024, the lowest in 19 years, due to poor box office performance affecting overall results [6]. - The company plans to focus on high-quality content, which may extend the development cycle of new projects and increase production costs, leading to a decline in profit expectations over the next few years [6]. - The derivative products and other copyright operations have shown positive progress, with a revenue increase of 36% in 2024, excluding New Classics Media [6].

——安踏体育（2020.HK）2024 年业绩点评 买入（维持） 当前价：93.15 元港币 2025 年 3 月 20 日 公司研究 24 年主营业绩健康增长，多品牌龙头优势继续凸显 分析师：姜浩 执业证书编号：S0930522010001 021-52523680 jianghao@ebscn.com 分析师：孙未未 执业证书编号：S0930517080001 021-52523672 sunww@ebscn.com 分析师：朱洁宇 执业证书编号：S0930523070004 021-52523842 zhujieyu@ebscn.com 市场数据 | 总股本(亿股) | 28.07 | | --- | --- | | 总市值(亿港元)： | 2614.92 | | 一年最低/最高(港元)： | 65.55/107.50 | | 近 3 月换手率： | 40.9% | 股价相对走势 -20% -10% 0% 10% 20% 30% 40% 50% 60% 24/01 24/02 24/03 24/04 24/05 24/06 24/07 24/08 24/09 24/10 24/11 24/12 25/0 ...

联合研究丨港股公司深度丨中国燃气（0384.HK） [Table_Title] 中国燃气：高股息燃气龙头，顺价带动毛差回升 %% %% %% %% research.95579.com 1 丨证券研究报告丨 [Table_Summary] 中国燃气是中国最大的城燃公司之一，从此前的跑马圈地式高速发展逐渐过渡到目前的稳健经 营阶段，近两年分红金额维持在 27.2 亿港元，股息率约 7%。受益于居民燃气顺价和上游采购 成本下降带来毛差修复；燃气接驳工程业绩占比已到低位，我们预计自 2024/25 财年开始将扭 转此前业绩大幅下滑的趋势，EPS 重新恢复增长。PB 和 PE 估值仍处低位，看好公司价值重 估机会。 报告要点 分析师及联系人 [Table_Author] SAC：S0490517090001 SAC：S0490517080003 SAC：S0490520070003 SFC：BUV415 SFC：BQT627 宋尚骞 SAC：S0490520110001 徐科 张韦华 贾少波 请阅读最后评级说明和重要声明 2 / 30 %% %% %% %% research.95579.com 中国燃气 2023 ...

Investment Rating - The report maintains an "Outperform" rating for the company, indicating an expected relative performance exceeding the benchmark index by over 10% in the next 12-18 months [2][8]. Core Insights - The company achieved a revenue of 40.87 billion RMB in 2024, representing a 33% year-over-year increase, with Q4 revenue reaching 16.11 billion RMB, up 23% year-over-year and 59% quarter-over-quarter [8]. - The net loss for 2024 was narrowed to 5.79 billion RMB, with Q4 net loss at 1.33 billion RMB, showing improvement [8]. - Vehicle sales revenue in Q4 was 14.67 billion RMB, up 20% year-over-year and 67% quarter-over-quarter, driven by increased deliveries of 92,000 units, which is a 52% year-over-year and 97% quarter-over-quarter increase [8]. - The company is expected to continue strong performance in 2025, with a forecast of 91,000-93,000 vehicle deliveries in Q1, representing a year-over-year increase of 317%-326% [8]. Financial Data and Forecast - Revenue projections for 2025, 2026, and 2027 are 90.83 billion RMB, 130.71 billion RMB, and 152.66 billion RMB respectively, with net profits expected to be -1.2 billion RMB, 2.9 billion RMB, and 6.5 billion RMB [2][8]. - The gross profit margin (GPM) improved to 14.3% in 2024, up 12.8 percentage points year-over-year, with Q4 GPM at 14.4% [8]. - The company plans to expand its global presence, targeting over 60 countries by the end of 2025, with a goal for overseas sales to account for 50% of total sales in the next 10 years [8]. Valuation - The report uses the Price-to-Sales (PS) method for valuation, estimating PS ratios of 1.8, 1.3, and 1.1 for 2025, 2026, and 2027 respectively [8]. - The target price is set at 103.90 HKD, based on a PS of 2.0 times for 2025 [8].

Investment Rating - The report maintains a "Hold" rating for Kingdee International (268 HK) with a target price of HK$14.94, indicating a potential downside of 1% from the current price of HK$15.14 [1][8]. Core Views - The report highlights that Kingdee's stock price has increased by 94% year-to-date, outperforming the Hang Seng Index, which rose by 23%. However, the company's fundamental recovery is lagging behind this valuation increase [6]. - For the second half of 2024, Kingdee's revenue grew by 9% year-on-year to RMB 3.39 billion, which was below market expectations. The annual recurring revenue (ARR) increased by 20% to RMB 3.43 billion, also falling short of expectations [6][10]. - The report notes that Kingdee's cloud service revenue grew by 10% year-on-year to RMB 2.72 billion, again below market consensus [6][10]. - The management expects ARR to grow by approximately 20% in 2025, with revenue growth anticipated to accelerate to 14% year-on-year [6][10]. Summary by Sections Investment Rating and Price Target - The target price has been raised from HK$6.38 to HK$14.94, reflecting a significant increase of 134% [2][12]. - The current valuation is aligned with global peers, with a projected P/S ratio of 7.0, up from 2.8 [8][12]. Financial Performance - For 2025, the expected revenue is RMB 7.15 billion, with a year-on-year growth of 14% [9][10]. - The report projects a net profit of RMB 176 million for 2025, with an EPS of RMB 0.05 [9][10]. - The operating profit is expected to reach RMB 75 million in 2025, indicating a return to profitability [9][10]. Adjustments and Forecasts - Due to underperformance in the second half of 2024, revenue forecasts for 2025 and 2026 have been adjusted downwards by 3% and 5%, respectively [7][10]. - The ARR forecast for 2025 has been revised to a growth of 22%, down from previous estimates [7][10]. Market Comparison - Kingdee's market capitalization is approximately US$6.99 billion, with a three-month average daily trading volume of US$89 million [1][12]. - The report compares Kingdee's performance with global peers like SAP and Workday, noting that Kingdee's revenue growth and AI monetization capabilities are still developing [8][12].

SDICSI 2025 年 3 月 19 日 东曜药业-B (1875.HK) 朴欣汀收入同比增长 42%，预计 2025 年完成首个海外国家获批。 2024 年公司产品收入为 8.77 亿元，同比增长 39%，主要来自核心产品朴欣汀的 贡献。朴欣汀于 2021 年上市，2022 年纳入乙类医保目录，已覆盖原研药 Avastin 在中国大陆获批的六项适应症。2024 年朴欣汀销售收入同比增长 42%。 截至 2024 年 12 月 31 日，公司已启动 34 个海外国家的上市注册申请工作，已 有 20 个国家的上市申请文件获得受理，产品已取得哥伦比亚、埃及以及印尼等 国家的 GMP 证书，预计 2025 年完成首个海外国家获批，为全球化战略发展奠 定重要里程碑。 投资建议：我们预计公司 2025-2027 年收入分别为 12.8 亿元/13.3 亿元/14.2 亿 元，净利润分别为 47 百万元/82 百万元/138 百万元。 首次扭亏为盈，经营现金流连续三年正向 事件：2024 年业绩首次扭亏为盈，经营活动现金净额连续三年持续正向。 报告摘要 首次扭亏为盈，经营活动现金净额连续三年持续正向。 2024 年公 ...

2025 年 3 月 20 日 | 朱吉翔 | | | --- | --- | | H70138@capital.com.tw | | | 目标价(港币) | 65.0 | 公司基本资讯 | 产业别 | | | | | 电子 | | --- | --- | --- | --- | --- | --- | | H 股价(2025/03/20) | | | | | 56.50 | | 恒生指数(2025/03/20) | | | 24,220.0 | | | | 股价 12 个月高/低 | | | 58.2/13.08 | | | | 总发行股数(百万) | | | 25,111.69 | | | | H 股数(百万) | | | 20,595.40 | | | | H 市值(亿元) | | | 5,127.34 | | | | | | | ARK Trust (Hong | | | | 主要股东 | | | | | Kong) | | | | Limited(25.02% | | | | | | | | | | ) | | 每股净值(元) | | | | | 7.52 | | 股价/账面净值 | | | | | ...